Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer have?
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer has 1,813 citations in the OpenAlex counts ScholarIQ stores.
When was Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer published?
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer has 2021 year in the ScholarIQ index.
What is the open-access status of Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer?
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer has bronze oa status in the ScholarIQ index.
What is the DOI of Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer?
The DOI for Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer is on the source record.
What is the PMID of Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer?
The PMID for Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer is on the source record.
What is the OpenAlex record for Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer?
The OpenAlex for Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer is on the source record.